

Product Data Sheet

Product Name: Sulindac-d3

Cat. No.: GC48677

Chemical Properties

Cas. No.

SMILES OC(CC1=C(C)/C(C2=CC=C(F)C=C21)=C/C3=CC=C(C=C3)S(C([2H]))([2H])[2H])=O)=O


Formula C20H14D3FO3S M.Wt 359.4

Solubility DMSO : 50 mg/mL (140.29 mM; Storage -20°C
Need ultrasonic); H₂O : < 0.1 mg/mL
(insoluble)

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

Sulindac-d₃ is intended for use as an internal standard for the quantification of sulindac by GC- or

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

LC-MS. Sulindac is a non-steroidal anti-inflammatory drug (NSAID), selective COX-2 inhibitor (IC_{50} s = 0.79 and >1,000 μ M for COX-2 and COX-1, respectively), and prodrug form of sulindac sulfide.^{1,2,3,4} Sulindac is reduced by intestinal bacteria to form sulindac sulfide.¹ It inhibits acetic acid-induced writhing in mice and reduces paw edema induced by carrageenan in rats when administered at a dose of 100 mg/kg.³ Sulindac (60 mg/kg) reduces tumor growth in MiaPaCa-2 and BxPC-3 mouse xenograft models.⁴ Formulations containing sulindac have been used in the treatment of pain associated with arthritis, ankylosing spondylitis, and gout.

1. Maseda, D., and Ricciotti, E. NSAID-gut microbiota interactions. *Front. Pharmacol.* 11:1153 (2020)
2. Grossman, C.J., Wiseman, J., Lucas, F.S., et al. Inhibition of constitutive and inducible cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and Cox 2 inhibitors. *Inflamm. Res.* 44(6):253-257 (1995)
3. Bhat, M.A., Al-Omar, M.A., Alsaif, N.A., et al. Novel sulindac derivatives: Synthesis, characterisation, evaluation of antioxidant, analgesic, anti-inflammatory, ulcerogenic and COX-2 inhibition activity. *J. Enzyme Inhib. Med. Chem.* 35(1):921-934 (2020)
4. Yip-Schneider, M.T., Wu, H., Ralstin, M., et al. Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. *Mol. Cancer Ther.* 6(6):1736-1744 (2007)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA